Brenntag, DE000A1DAHH0

Brenntag signs distribution agreement; stock pre-market at EUR 63.49

Published on 10/14/2026 at 08:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Brenntag announced an October 12 distribution deal with Cassava Pharma. The stock was at EUR 63.49 pre-market at 8:27 a.m. CEST on October 14 at Lang & Schwarz.

Dates and valuation

  • Brenntag announced an exclusive distribution agreement on October 12, 2026.
  • Brenntag stock was at EUR 63.49 at 8:27 a.m. CEST on October 14, 2026, in pre-market trading at Lang & Schwarz.
  • The October 13, 2026 research note cited a 7x 2027 EV-to-operating-EBITDA valuation against a fair multiple of 8x.
Farbige Pop-Art-Comic-Illustration eines Tankfahrzeugs vor einem Chemiewerk
Farbenfrohe Pop-Art-Comic-Szene mit Tankfahrzeug und Fässern zeigt stilisiert die Branche von Brenntag SE DE000A1DAHH0, Illustration mit AI erstellt.

On October 12, 2026, Brenntag announced an exclusive distribution agreement with Cassava Pharma for patented tapioca starch technology across the American personal-care market. The agreement expands Brenntag's Beauty & Personal Care portfolio in the United States. Brenntag identified applications including deodorants, dry shampoos, skin care and color cosmetics.

Pre-market indication

Brenntag stock was at EUR 63.49 at 8:27 a.m. CEST on October 14, 2026, in pre-market trading at Lang & Schwarz. The bid was EUR 63.36 and the ask was EUR 63.62. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Brenntag stock.

What matters today: Brenntag's latest company announcement is dated October 12, 2026. The cited research sets a EUR 65.00 target, 2.38 percent above the Lang & Schwarz indication. The same October 13, 2026 note cites a 7x 2027 EV-to-operating-EBITDA valuation against a fair multiple of 8x.

Recent company announcement

Brenntag said the agreement gives customers access to Cassava Pharma's U.S.-sourced tapioca solutions, along with technical support for product selection and application development. Brenntag Specialties North America described the partnership as an addition to its sustainable, high-performance sensory-powders portfolio. The company release did not disclose financial terms.

Analyst view

In a note dated October 13, 2026, mwb research expected third-quarter operating EBITDA of EUR 385 million, citing the fading effect of exceptional pricing factors and broadly stable underlying volumes. The note maintained a EUR 65.00 price target and a Hold recommendation. FinanzNachrichten.de published the research summary.

Market context: Market report DAX.

More news and analysis on Brenntag stock

Disclaimer...

en | DE000A1DAHH0 | BRENNTAG | boerse | 70321368 | bgmi